FOLLOW US

In a landmark move that could reshape the global consumer health and hygiene market, Kimberly-Clark Corp., the maker of Huggies and Kleenex, announced Monday it will acquire Kenvue, the Tylenol and Band-Aid parent company, in a deal valued at approximately $48.7 billion.

The transaction, which has already received unanimous approval from both companies’ boards, will unite two powerhouse portfolios of household staples—from Kleenex, Kotex, and Scott to Tylenol, Neutrogena, Aveeno, and Listerine—creating a new global titan in the health and personal care industry.

Legal and Financial Heavyweights Behind the Deal

A formidable lineup of legal and financial advisors is steering the high-stakes acquisition. Kirkland & Ellis LLP leads counsel for Kimberly-Clark, joined by Gibson Dunn & Crutcher LLP and Arnold & Porter Kaye Scholer LLP on specialized legal and healthcare matters. Cravath, Swaine & Moore LLP is representing Kenvue.

On the financial side, PJT Partners LP and J.P. Morgan Securities are advising Kimberly-Clark, while Centerview Partners and Goldman Sachs & Co. represent Kenvue.

Financing will come through existing cash, new debt issuance, and proceeds from the upcoming sale of a 51% stake in Kimberly-Clark’s international family care and professional unit. JPMorgan Chase Bank NA has committed to the funding package.

Inside the Merger: Strategic Synergies and Financial Impact

Under the merger terms, Kenvue shareholders will receive $3.50 in cash and 0.14625 shares of Kimberly-Clark stock for each Kenvue share—equaling $21.01 per share based on Kimberly-Clark’s recent closing price.

The combined entity is projected to generate $32 billion in annual revenue and $7 billion in adjusted EBITDA, with ten brands each topping $1 billion in yearly sales. Kimberly-Clark anticipates $1.9 billion in cost synergies and $500 million in profit growth within four years, partly offset by $300 million in reinvestment costs.

“Kenvue is uniquely positioned at the intersection of consumer goods and healthcare, with exceptional talent and brand strength,” said Mike Hsu, Kimberly-Clark’s chairman and CEO, who will also lead the merged company.

A New Era for Global Consumer Health

Kenvue, spun off from Johnson & Johnson in August 2023 at a valuation exceeding $40 billion, now steps into a new chapter under Kimberly-Clark’s ownership.

“Bringing together Kenvue and Kimberly-Clark creates a uniquely positioned global leader in consumer health with a broader range of new growth opportunities ahead,” said Larry Merlo, Kenvue’s board chair.

Three Kenvue board members will join Kimberly-Clark’s board upon closing, expected in the second half of 2026, pending regulatory and shareholder approvals.